Opinion|Videos|October 28, 2024
Integrating Tisotumab Vedotin into Ovarian Cancer Therapy
Panelists discuss the integration of tisotumab vedotin into ovarian cancer therapy, covering its role in treatment approaches, patient selection, adverse event management, clinical pearls, challenges in practice, and the implications of the drug’s payload on treatment efficacy.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Where does tisotumab vedotin fit in your current treatment approach?
- In which patients do you consider this treatment option?
- Adverse event management and clinical pearls
- What challenges do you see in practice with tisotumab vedotin, and how do you approach associated management?
- Payload of tisotumab vedotin
Advertisement
Related to this article
Neeta Somaiah, MD, discusses the significance of the Peak study and what an approval of bezuclastinib plus sunitinib would mean for GIST.
Sara Nunnery, MD, MSCI, and Irene M. Kang, MD, discuss toxicity and monitoring considerations for the use of ADCs in metastatic TNBC.
The NMPA accepted the NDA for the PD-L1/4-1BB–directed bispecific antibody opamtistomig in previously treated advanced extrapulmonary NEC.
Obesity can weaken the immune system and lead to disease progression, but Roswell Park experts revealed that exercise may reverse that effect.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
The European Commission approved teclistamab plus daratumumab for relapsed/refractory multiple myeloma after at least 1 prior therapy, offering the regimen as early as second line.
ASCO’s ctDNA guidelines support testing for genetic alterations in select scenarios but do not endorse it for residual disease or recurrence monitoring.
Updated ASCO Living Guideline recommendations expand frontline therapy for HER2-positive gastroesophageal cancer to include zanidatamab-based regimens.
Advertisement
Advertisement
Trending on OncLive
1
ASCO Guideline Update Broadens First-Line Treatment Options for HER2+ Gastroesophageal Cancer
2
CAR T-Cell Therapy Continues to Make Its Case in Early Relapsed Myeloma
3
FDA Awards Fast Track Designation to Safusidenib in IDH1-Mutant Glioma
4
European Commission Approves Teclistamab Plus Daratumumab for R/R Myeloma
5